Oroset (Ondansetron)

Ondansetron, the active ingredient in Oroset, is a 5‑HT3 receptor antagonist presented as an oral tablet for oral use. It prevents nausea and vomiting associated with chemotherapy, postoperative recovery, and radiation therapy.

GNH USA supplies Oroset as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Oroset, a selective 5‑HT3 receptor antagonist, is used to control nausea and vomiting in several clinical settings. - Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting caused by anticancer drugs. - Postoperative nausea and vomiting: lowers the incidence of nausea and vomiting after surgical procedures. - Radiation‑induced nausea and vomiting: helps control symptoms in patients receiving radiotherapy.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements leading to hard stools. - Diarrhoea: loose, watery stools. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - QT interval prolongation: potential heart rhythm disturbances. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Serotonin syndrome: agitation, fever, rapid heart rate when combined with other serotonergic drugs. - Cardiac arrhythmias: irregular heartbeats that may be life‑threatening. - Stevens‑Johnson syndrome: severe skin blistering and detachment. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before prescribing, consider the following precautions: - Cardiac risk assessment: evaluate patient history for arrhythmias or prolonged QT interval. - Electrolyte monitoring: correct hypokalaemia or hypomagnesaemia which can exacerbate QT prolongation. - Hepatic impairment: adjust use in patients with severe liver dysfunction. - Hypersensitivity: avoid in individuals with known allergy to ondansetron or similar compounds. - Concomitant QT‑prolonging drugs: use with caution when other agents that affect cardiac repolarisation are present. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines; awareness of the interaction level is essential. Major Interactions (Avoid): - Apomorphine: co‑administration can cause severe hypotension and loss of consciousness. - Other QT‑prolonging agents (e.g., quinidine, erythromycin, haloperidol): increase risk of cardiac arrhythmias. - Carbamazepine: induces metabolism, potentially reducing ondansetron efficacy. Moderate Interactions (Monitor Closely): - Aprepitant: may increase ondansetron plasma concentrations. - Dexamethasone: combined use may enhance anti‑emetic effect. - Serotonergic drugs (e.g., SSRIs, tramadol): monitor for signs of serotonin syndrome.